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effectiveness ratio was $32,828.60, indicating the cost of
avoiding each additional fracture using the less desirable
calcium therapy. The cardioprotective effect of hormone
therapy accounted for nearly 3 additional years of life for
each woman on therapy.
CONCLUSIONS: Hormone replacement therapy in con-
junction with calcium supplementation is far more cost-
effective than calcium supplementation alone.
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Post-menopausal hormone replacement therapies (HRT)
represent a significant long-term pharmacological treat-
ment that is associated with multiple beneficial clinical
outcomes. However, HRT is associated with a significant
reduction in patient compliance over time.
OBJECTIVE: To determine the impact of periodically
mailed patient educational materials on HRT compliance.
METHODS: Using centralized pharmacy records from a
managed-care organization, both retrospective baseline
(12 months preceding mailings) and prospective (12
months following mailings) compliance indices were ana-
lyzed for three cohorts of patients: Cohort A = patients
who were receiving material prior to program initiation;
Cohort B = patients who were offered material but de-
clined; and Cohort C = patients who had not previously
received material but elected to do so during the study pe-
riod. Compliance indices included assessment of MED-
INT (number of days of medication), MED-TOT (total
medication) and MED-OUT (days without medication).
Patients were identified as "compliant" if they had a
MED-TOT >75% or a MED-OUT <25%.
RESULTS: 584 patients (Cohort A = 149, Cohort B =
245, and Cohort C = 190) were included in analyses.
During the retrospective baseline period, all three cohorts
had statistically similar compliance indices. Analyses of
data collected during the prospective period indicated
that, compared to Cohort B, significant (p < 0.01) be-
tween-group improvements in each of the compliance in-
dices were observed. Furthermore, the greatest overall
improvements from baseline were observed in Cohort C,
and Cohort C demonstrated a significant (p < 0.01) in-
crease in number of "compliant" patients compared to
Cohort B.
CONCLUSION: These results suggest that educational
material significantly improves patient compliance, and
the effect can be directly observed by assessing central-
ized pharmacy records.
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OBJECTIVES: To study differences among two regimens
of estrogen/progestin replacement therapy in post-meno-
pausal women with respect to quality of life, pharrnacoeco-
nomics, bleeding pattern, compliance, and safety profile.
METHODS: A 12-center, randomized, comparative dose
study was conducted in 183 women (mean age: 53.9
years) randomized to one of two treatment arms:
Prometrium" 200 mg (n = 90) or Provera® 5 mg (n =
93) administered in a single daily dose for 14 days in a
3D-day cycle. All patients received 0.625 mg Premarin®
for 25 of the 30 days. Quality of life was measured by the
Nottingham Health Profile (NHP), Woman's Health
Questionnaire (WHQ), and Short Form 36 (SF-36).
RESULTS: Improvements in climacteric symptoms were
observed between baseline and month 9 within both
groups. All domains within the NHP and WHQ im-
proved significantly for both patient groups (p < 0.008),
and greater improvements were observed for Prometrium
patients in the Menstrual Problems and Cognitive Diffi-
culties domains of the WHQ. While Prometrium patients
reported an improvement in the Menstrual Problems do-
main, Provera patients reported a worsening. The num-
ber of cycles with bleeding was significantly higher for
the Provera patients (p = 0.001). Average nine-month so-
cietal menopausal costs/patient were $367 ± $120 (Cdn)
for Prometrium patients and $360 ± $369 (Cdn) for
Provera patients (not statistically significant). Although
costs were variable, offsetting savings for Prometrium pa-
tients were observed in out-of-pocket expenses and
missed time from work.
CONCLUSIONS: This study highlights important qual-
ity of life and cost aspects of Prometrium and Provera use
that may impact longer term compliance when patients
use Prometrium + Premarin regimens.
